CLINICAL TRIALS: THERAPEUTIC OPPORTUNITIES, ECONOMIC IMPACT AND SAVINGS FOR THE NATIONAL HEALTH SYSTEM
6ER-015
IMPACT ON PAIN MANAGEMENT AFTER A SINGLE VISCOSUPPLEMENTATION INTRAARTICULAR INJECTION IN PATIENTS WITH HIP OSTEOARTHRITIS WHO FAILED CONVENTIONAL TREATMENT
6ER-014
PLATELET-RICH PLASMA: WHAT ARE WE REALLY ADMINISTERING TO OUR PATIENTS?
6ER-013
A PILOT RANDOMISED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL OF PROPHYLACTIC SILDENAFIL IN PRETERM INFANTS AT RISK OF BRONCHOPULMONARY DYSPLASIA
6ER-012
EFFICACY AND SAFETY ANALYSIS OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
6ER-011
MODELLING THE IMPACT OF DISCOUNTS ON THE REAL-LIFE COST-EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SPAIN
6ER-010
PUBLIC KNOWLEDGE AND PERCEPTION TOWARDS VACCINES IN ITALY
6ER-009
PATIENT SATISFACTION AND KNOWLEDGE AFTER SWITCHING FROM EVIPLERA TO ODEFSEY
6ER-008
PERSISTENCE AND REASONS FOR SWITCHING THE INITIAL ANTIRETROVIRAL TREATMENT IN A COHORT OF NAÏVE HIV-INFECTED PATIENTS
6ER-007
OFF-LABEL USE OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS: EFFECTIVENESS, SAFETY AND COST IN CLINICAL PRACTICE
6ER-006
EFFECTS OF STATINS USE ON CLINICAL OUTCOMES IN PATIENTS ADMITTED WITH COMMUNITY-ACQUIRED PNEUMONIA
6ER-005
USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE
6ER-003
COST OF VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS WITH LUNG AND PROSTATE CANCE: COSTECAT STUDY
6ER-002
EFFICACY OF A FIXED-RATIO COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
6ER-001
HIGH VERSUS LOW DOSE OF URSODEOXYCHOLIC ACID FOR THE MANAGEMENT OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY: A COHORT RETROSPECTIVE STUDY OF MATERNAL AND NEONATAL OUTCOMES
